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The emergence of carbapenemase-producing Enterobacterales (CPE) as a major cause of invasive infection both
within the UK and internationally poses a very real concern for all providers of healthcare. The burden of morbid-
ity and mortality associated with CPE infections is well described. The need for early, targeted, effective and safe
antimicrobial therapy remains key for the management of these infected patients yet reliable antimicrobial
treatment options remain scarce. In the absence of a universal treatment for these CPE invasive infections,
individual treatment options tailored to susceptibilities and severity of infection are required. This working
group from within the UK Clinical Pharmacy Association (UKCPA) Pharmacy Infection Network has developed
evidence-based treatment recommendations to support infection specialists in managing these complex
infections. A systematic review of peer-reviewed research was performed and analysed. We report consensus
recommendations for the management of CPE-associated infections. The national expert panel makes thera-
peutic recommendations regarding the pharmacokinetic and pharmacodynamic properties of the drugs and
pharmacokinetic targets, dosing, dosage adjustment and monitoring of parameters for novel and established
antimicrobial therapies with CPE activity. This manuscript provides the infection specialist with pragmatic and
evidence-based options for the management of CPE infections.
1. Introduction
This guidance has been prepared by a working group of specialist
antimicrobial and infectious diseases pharmacists within the UK
Clinical Pharmacy Association (UKCPA) specialist group, Pharmacy
Infection Network (PIN). The guidance advises on the safe and ef-
fective antimicrobial treatment of carbapenemase-producing
Enterobacterales (CPE) infections. There are accompanying recom-
mendations for the appropriate infection prevention and control
precautions advised for CPE in addition to treatment advice pro-
vided by the Working Party of the British Society for Antimicrobial
Chemotherapy (BSAC), the Healthcare Infection Society (HIS) and
the British Infection Association (BIA) to advise on the treatment
of infections caused by MDR Gram-negative bacteria.1,2
1.1. What is the scope of this manuscript?
We examine the background information and available published
literature and then (i) propose a series of treatment principles, (ii)
review the place in therapy of antimicrobial treatments that may
be effective for treatment of CPE infections and (iii) advise on dose
optimization to maximize treatment response. These recommen-
dations should be interpreted based on available susceptibilities
and read in conjunction with the BSAC/HIS/BIA guidance on treat-
ment of infections caused by MDR Gram-negative bacteria.
These recommendations advise on the treatment for
Enterobacterales with acquired carbapenemases, specifically
NDM, VIM, IMP, KPC and OXA-48 [as defined by UK Standards
for Microbiology Investigations: Detection of bacteria with
carbapenem-hydrolysing b-lactamases (carbapenemases)].1
These recommendations do not include advice on the manage-
ment of MDR non-Enterobacterales pathogens or carbapenem-
resistant Enterobacterales with non-carbapenemase resistance
mechanisms. Acinetobacter and Pseudomonas spp. may host
several mechanisms conferring resistance to carbapenems,
including carbapenemases (class D and class B), porin loss (e.g.
reduced expression or polymorphism) and multidrug efflux
pumps. An attempt has been made to include information
relating to these organisms where possible. Pathogens with
intrinsic carbapenem resistance are outside the scope of this
review.
VC The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy.
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These recommendations do not include specific information
relating to dosing and treatment options for CPE infections in
neonates and children.
These recommendations do include information on the use
of unlicensed treatments, dosing and methods of administra-
tion that have been reported in the literature or theoretically
have potential to maximize therapeutic effect. It is the respon-
sibility of healthcare organizations to review the suitability
of these options on an individual-patient basis. Clinicians and
patients must be made aware of the unlicensed status when
using doses outside of the UK marketing authorization. This
review has sought to include all therapies with a UK license
or promising therapies undergoing Phase III studies or awaiting
UK licensing.
1.2. What is the evidence for these recommendations?
A systematic review was performed of peer-reviewed research
using the searches shown in section 2.1. Experts from the working
group were used to appraise the literature and provide consensus
recommendations in the absence of clear evidence-based
recommendations.
1.3. How frequently are the recommendations reviewed
and updated?
These recommendations will be reviewed and updated every
5 years, as warranted by the emerging literature or by the availabil-
ity of new therapies.
1.4. Defining CPE infections
Carbapenemases are enzymes that hydrolyse carbapenem antibi-
otics, conferring resistance. They are produced by a small but
growing number of Enterobacterales strains. The presence of a
carbapenemase does not always result in high-level resistance to
carbapenems in vitro. There are different types of carbapenemase,
of which KPC, OXA-48, NDM and VIM enzymes are currently the
most commonly identified within the UK. Carbapenemases include
enzymes from b-lactamase classes A, B and D (Ambler classifica-
tion). The main classes of acquired carbapenemases are listed in
Table 1.
1.5. Aim
The primary aim of the review was to assess the current available
evidence for the treatment options of CPE infections. Secondary
aims included: (i) analysing the optimum administration of
b-lactams for treatment of invasive CPE infections; (ii) providing
optimum dosing parameters for antimicrobial therapies; and (iii)
reviewing the role of single and combination therapy for the treat-
ment of CPE infection.
2. Methodology
2.1 Evidence appraisal
A literature review was conducted to identify CPE-related treat-
ment options and data included were identified by searches of
MEDLINE, Embase and references from relevant original articles.
Secondary and tertiary literature was also reviewed, including
manufacturers’ product datasheets on individual therapies. Search
terms and main heading descriptors (Medical Subject Headings)
‘carbapenemase producing Enterobacterales’, ‘antimicrobial ther-
apy’, ‘antibiotic treatment’ and ‘treatment’ were included. Search
criteria were broad and intended to capture all CPE treatment
options. Prospective and retrospective articles in English that
reported original research on clinical patients or patient outcomes
of CPE infections in acute care were included. Studies focusing pre-
dominantly on non-Enterobacterales pathogens were excluded.
All articles were screened by one author (S.H.) and screened inde-
pendently by two authors (S.H. plus a second author) for each sub-
ject area. A flow chart of the systematic review process is given in
Figure S2 (available as Supplementary data at JAC-AMR Online).
All recommendations and dosing advice were based on
expert opinion and agreed upon within the working group. All three
senior authors (S.H., M.G. and J.S.) had to agree unanimously for a
recommendation to be included.
3. Recommendations for management of CPE
infections
The content of the manuscript has been derived from current
best peer-reviewed publications and expert opinion and support
existing BSAC/HIS/BIA guidance on treatment of infections caused
by MDR Gram-negative bacteria. General recommendations for
prescribers are outlined in Table 2. Specific antimicrobial dosing
advice is outlined in the drug monographs (Appendix S1).
3.1. General management of CPE infection
For the treatment of CPE infection, the following good practice
principles of infection management are advised.
(i) Antimicrobial therapy should be discussed with the local in-
fection specialist team (including microbiology and/or infec-
tious diseases clinicians and the antimicrobial or anti-
infective pharmacists) to agree a safe and effective tailored
treatment option for the patient.
(ii) Antimicrobial therapy should be initiated and administered
promptly and without any unnecessary delay in patients
with systemic evidence of CPE infection.
(iii) Antimicrobial therapy should be guided by recent or previous
culture and susceptibility results. These may vary between
strains, including samples obtained from a single patient
during a single infection.
(iv) Antimicrobial therapies should only be started in response
to symptoms of infection. Colonization with CPE does not
always correlate with active or invasive infection. Screening
Table 1. Common b-lactamase classes A, B and D (Ambler classification)
identified in Enterobacterales
b-lactamase class variant(s) b-lactamase class variant(s)
Class A (serine) KPC, GES
Class B (zinc) MBLs NDM, VIM, IMP
Class D (serine) OXA-48
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Table 2. Summary of recommendations for prescribers managing patients with CPE infection
Topic Recommendation Strength
Treatment of invasive
CPE infections
For non-severe presentation of urinary source infection, including BSI secondary to UTI, con-
sider use of monotherapy with a susceptible therapy with demonstrated efficacy for UTI/BSI
(e.g. b-lactam/b-lactamase inhibitor).
For severe infection, including all non-UTIs, consider use a minimum of two antibiotics to which
the organism is susceptible. There is insufficient evidence to conclude which combinations
are most effective.
For UTIs with no systemic involvement, consider treatment with a single agent that is known
to concentrate in the urine and to which the isolate is susceptible.
expert opinion
Dosing of antimicrobials For IV b-lactams requiring multiple daily dosing, consider administering as an extended or
continuous infusion to optimize T.MIC if:
(i) the MIC is high (intermediate or low-level resistance); or
(ii) for critical care patients with augmented renal function; or
(iii) infections in deep tissue, e.g. respiratory tract infection.
expert opinion
Antimicrobial-specific advice in CPE infection
aminoglycosides Where phenotypic susceptibilities are available, aminoglycosides can be used as part of
combination therapy to treat CPE infections.
Aminoglycoside antibiotics should be considered for treatment of UTIs where susceptibilities
allow.
expert opinion
b-lactam/b-lactamase
inhibitor therapy
Novel b-lactam/b-lactamase inhibitor combination therapies may be considered for monother-
apy or in combination therapy for treatment of invasive CPE infections where susceptibilities
known.
Meropenem/vaborbactam is recommended for treatment of invasive infections caused by
KPC-producing resistant Enterobacterales.
Ceftazidime/avibactam is recommended for treatment of invasive infections caused by KPC-
and OXA-48-producing resistant Enterobacterales. Isolates with KPC-3 resistance profile
should be treated with caution with ceftazidime/avibactam, as outlined by BSAC Expert
Committee.
Aztreonam in combination with avibactam (as ceftazidime/avibactam or aztreonam/
avibactam) may be considered as salvage treatment option for MBL-producing
Enterobacterales where other licensed therapies are unavailable.
expert opinion
carbapenems Carbapenems may be used in combination with other agents, including a second carbapenem.
Outcomes are likely to be improved if the organism appears susceptible on in vitro testing
(meropenem MIC8 mg/L) or is close to the breakpoint. High-dose meropenem and/or
extended administration therapy should be considered for organisms with an MIC of
4–8 mg/L.
There are insufficient data available to recommend the routine use of dual carbapenem ther-
apy to overcome CPE resistance mechanisms.
expert opinion
cefiderocol Cefiderocol-based therapy may be considered for combination therapy for invasive CPE
infections including Class B Ambler-expressing pathogens (NDM, IMP and VIM resistance
mechanisms).
expert opinion
ceftazidime Ceftazidime, and other third/fourth-generation cephalosporins, can be considered for the
treatment of OXA-48-producing CPE organisms where co-produced ESBLs or AmpC enzymes
are absent and where phenotypic susceptibilities are available. Ceftazidime is the preferred
third-generation cephalosporin as lower MIC values are generally found for
Enterobacterales.
expert opinion
ciprofloxacin Ciprofloxacin may be considered as part of combination therapy where isolates have
demonstrated in vitro susceptibility.
expert opinion
colistin Colistin is not recommended as monotherapy for systemic infections.
Colistin therapeutic drug monitoring is recommended for all patients treated with parenteral
treatment to minimize risk of toxicity.
expert opinion
co-trimoxazole When susceptibilities are known, co-trimoxazole may have a limited role in the treatment of
less severe CPE infections, especially UTIs.
Continued
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may identify colonized patients though rectal swab or stool
sample to inform local infection prevention and control
practice.
(v) Ongoing antimicrobial therapy should be reviewed daily to
confirm effectiveness. Regular review of treatment is advised
to assess the need for continued treatment and review the
potential for de-escalation or IV-to-oral switch where
appropriate.
(vi) Antimicrobial dosing should be tailored to the individual
patient and adapted to current renal and hepatic function,
body weight and suspected site of infection. Monitoring for
potential toxicities and adverse effects is recommended for
all patients on systemic antimicrobial therapy.
All antimicrobial treatment recommendations within this
guidance are based on the assumption of confirmed susceptible
isolates.
3.2. Use of combination versus monotherapy
antimicrobials for CPE infections
The use of combination therapy, defined as treatment with two or
more antimicrobials active against the CPE, has been much
debated over the last decade. (Note: b-lactam/b-lactamase inhibi-
tor therapies are described as a single therapy in this analysis.) The
main argument made for combination therapy is the potential for
synergy or additive effect of combination therapy to prevent selec-
tion of resistant pathogens and/or improve treatment outcomes.
Prior to the introduction of the novel b-lactam/b-lactamase
inhibitor therapies to clinical practice, analysis of invasive KPC
infections (n"105) identified that significantly more treatment
failures were seen with monotherapy (49% versus 25%; P"0.01)
from non-urinary sources.3 Also, higher rates of treatment failure
with monotherapy for respiratory tract infections were observed
(67% versus 29%; P"0.03). A 2014 systematic review of antibiotic
treatment of infections caused by CPE4 found that the majority of
studies did not show statistically significant differences in mortality
or treatment failures between combination therapy and mono-
therapy. However, three studies reviewed, including a total of 194
patients with bacteraemia, demonstrated a significantly lower
mortality with combination therapy, colistin/polymyxin B or tige-
cycline combined with a carbapenem. More recent (2018) analysis
of colistin monotherapy versus colistin plus meropenem failed to
demonstrate a survival benefit with combination therapy.5 This
work was done predominantly with Acinetobacter baumannii.
In the subgroup of CPE pathogens there was a non-significant
trend to favour combination therapy; the subgroup was under-
powered to demonstrate any clear benefit.
Some interpretation of these works is required. Firstly, the use
of tigecycline as monotherapy for any bloodstream infection (BSI)
is not routinely advised due to its inadequate serum levels.
Tigecycline should only be used for BSI in combination with
another agent; the addition of an aminoglycoside is commonly
used in practice. Secondly, many of the pathogens reported in
these retrospective studies were non-Enterobacterales, notably
A. baumannii. The resistance mechanisms may differ with these
organisms and the clinical presentation and source of infection
may differ from Enterobacterales. And finally, the time to effective
therapy differs greatly in these retrospective studies but remains
possibly the greatest predictor of treatment outcomes. Early
targeted therapy is imperative for the optimum management of
these patients. Many of the retrospective studies analysed
Table 2. Continued
Topic Recommendation Strength
fosfomycin Fosfomycin IV is recommended to be used in combination with other active agents when used
for systemic therapy, due to its vulnerability to acquired resistance.
expert opinion
plazomicin Plazomicin IV may be considered as part of combination therapy where isolates have demon-
strated in vitro susceptibility.
Therapeutic drug monitoring is advised in patients with concurrent renal dysfunction or requir-
ing prolonged therapy (.72 h) to exclude accumulation and toxicity.
expert opinion
rifampicin The use of rifampicin for non-Acinetobacter spp. is not recommended due to the lack of in vivo
study data supporting its use.
expert opinion
tigecycline Tigecycline may be considered as part of combination therapy where isolates have demon-
strated in vitro susceptibility.
Tigecycline is not recommended for UTIs due to inadequate urinary tigecycline concentrations
required for therapeutic activity.
A high-dose tigecycline regimen (100 mg IV q12h) should be considered when treating patho-
gens with high MIC (0.5–2 mg/L) and/or in the treatment of respiratory infections.
expert opinion
temocillin Temocillin may be considered in combination with other active agents for KPC-producing
organisms where susceptibilities are known.
High-dose temocillin (6 g/day) is recommended for the treatment of invasive KPC infections of
non-urinary source.
The use of monotherapy temocillin (4 g/day) for the treatment of uncomplicated UTI with KPC
organisms should be considered where susceptibilities are known.
expert opinion
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randomized patients late in therapy or after ‘failed’ initial treat-
ments; these may impair treatment outcomes and make direct
study comparison challenging.
There are emerging data to identify the patient groups where
monotherapy may be considered. The INCREMENT study highlights
that combination therapy only results in improved survival among
patients with a high probability of death as defined by their
INCREMENT-CPE mortality score (an adapted Pitt bacteraemia
score) (see Figure S1).6 Patients with urinary or biliary tree infec-
tions and reduced acuity of infection on presentation may be safe-
ly trialled on single directed therapy (if available).
The new b-lactamase inhibitor therapies (combinations of avi-
bactam, vaborbactam or relebactam with a Gram-negative agent)
with activity against CPE are associated with non-inferior treat-
ment outcomes to standard of care. The randomized, prospective,
open-label, comparative study that compared meropenem/vabor-
bactam with best available antibiotic treatment for complex CPE
infections reported non-inferior clinical cure and 28 day mortality
rates.7 Observational study of ceftazidime/avibactam for CPE com-
pared with colistin is clouded by the use of additional anti-CPE
therapies, therefore the suitability of monotherapy is assumed but
cannot be safely confirmed. The RESTORE-IMI 1 publication reports
non-inferior clinical outcomes with imipenem/cilastatin/relebac-
tam versus imipenem/cilastatin plus colistin but is predominantly
tested against carbapenem-resistant Pseudomonas. Whilst
excellent clinical cure rates and trend to improved mortality are
demonstrated, the applicability of these imipenem/cilastatin/rele-
bactam results to non-Pseudomonas organisms remains unclear.
There are currently no data to inform whether combination
therapy prevents or promotes emergence of resistance in this
setting.
Recommendations
• For non-severe presentation of urinary source infection, includ-
ing BSI secondary to urinary tract infections (UTIs), consider use
of monotherapy with a susceptible therapy with demonstrated
efficacy for UTI/BSI (e.g. b-lactam/b-lactamase inhibitor).
• For severe infection, including respiratory tract infections,
consider use of a minimum of two antibiotics to which the or-
ganism is susceptible. There is insufficient evidence to conclude
which combinations are most effective.
3.3. Treatment of CPE UTIs
For renally excreted antimicrobials, accumulation of therapeutic
drug in the urinary tract may achieve the desired therapeutic con-
centrations to overcome low-level resistance. The high therapeutic
concentration within the urinary tract may therefore be sufficient
for monotherapy treatment in uncomplicated urinary infections.
The review by Lee and Burgess3 found an 81% success rate (9/11)
in patients treated for UTIs, with 8 of these cases treated with
monotherapy.
Aminoglycoside therapy resulted in a significantly higher rate
of microbiological clearance of carbapenem-resistant Klebsiella
pneumoniae in the urine compared with polymyxin B or tigecycline
in one study.8 There was no difference in failure rates between
aminoglycoside monotherapy and combination therapy (0/6 and
4/24, respectively; P"0.6) in the study by Lee and Burgess3 men-
tioned above. Patients successfully treated with monotherapy
included those with BSIs (n"3) and UTIs (n"2).
Enterobacterales with carbapenemase resistance mechanisms
may retain phenotypic susceptibility to co-trimoxazole. When sus-
ceptibilities are known, co-trimoxazole may have a limited role
in the treatment of less severe CPE infections, especially UTIs.
Surveillance data from the CRACKLE registry demonstrates suscep-
tibility rates of less than 30% for tested CPE isolates.9,10
Tigecycline has inadequate therapeutic levels in the urinary
system for effective therapeutic use. Whilst some case studies
have reported success with tigecycline in UTI, there is insufficient
evidence to recommend the use of tigecycline for the manage-
ment of UTI.
Recommendations
• For UTIs with no systemic involvement, consider treating with a
single agent that is known to concentrate in the urine and to
which the isolate is susceptible.
• Aminoglycoside antibiotics should be considered for treatment
of UTIs where susceptibilities allow.
• Tigecycline is not recommended for treatment of UTIs due to
suboptimal drug levels within the urinary system.
3.4. Optimizing administration of antimicrobials
Pharmacokinetic/pharmacodynamic principles should be used to
optimize (improve efficacy and minimize toxicity) antimicrobial util-
ization when possible. This is due to increasing antimicrobial resist-
ance and limited availability of novel antimicrobial agents. Consider
administering antimicrobials with short half-lives that exhibit
time-dependent antimicrobial activity (e.g.b-lactam agents) by pro-
longed infusion as this dosing strategy results in an increased likeli-
hood of optimal antimicrobial activity. Extended infusions, defined
as a drug administered over 3–4 h, or continuous infusions, defined
as a drug administered over 24 h, of b-lactams will increase the
time above the MIC (T.MIC).
11 The true benefit of extended infusion/
continuous infusion administration of b-lactams is expected with
high-MIC pathogens [intermediate (or susceptible, increased
exposure) or low-level resistance]. Patients infected with low-MIC
pathogens and/or not critically unwell are not likely to benefit from
b-lactams being administered by extended infusion/continuous
infusion. Infection in difficult-to-penetrate tissue (e.g. respiratory)
may benefit more from administration by extended infusion/con-
tinuous infusion.12 The BLING III study is a prospective, randomized
controlled trial that aims to address this hypothesis in critical care
patients requiring anti-pseudomonal b-lactams.13
Recommendations
• For IV b-lactams requiring multiple daily dosing, consider
administering as an extended or continuous infusion to opti-
mize T.MIC if:
(i) the MIC is high (intermediate or low-level resistance); or
(ii) for critical care patients with augmented renal function; or
(iii) infections in deep tissue, e.g. respiratory tract infection.
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3.5. Role of carbapenems in CPE infections
Several studies have demonstrated that combination therapy
involving a carbapenem is effective. In a review of 105 cases of KPC
infection, treatment failure was higher with carbapenem mono-
therapy compared with carbapenem-based combination therapy
(60% versus 26%).3 In an Italian multicentre study of 447 patients
with KPC-producing K. pneumoniae, combination therapy
with tigecycline, colistin and meropenem (2 g meropenem q8h
infused over an extended period of 3 h) was associated with lower
mortality (OR 0.52; 95% CI 0.35–0.77).14 Combinations that
included meropenem were associated with significantly higher
survival rates when the KPC-producing K. pneumoniae isolate had
a meropenem MIC of 8 mg/L. How this translates to other non-
KPC-producing CPE resistance mechanisms is less clear.
There have been some published data reviewing the use of
dual carbapenems for CPE infections. Ertapenem, usually in com-
bination with meropenem, has been used to treat infections
with KPC-producing pathogens. Ertapenem exploits its higher
carbapenemase affinity to act as a suicide substrate thus leading
meropenem to exert its antimicrobial activity. The clinical efficacy
of this dual therapy is unclear and with the recent introduction
of novel b-lactamase inhibitors, the clinical need for it is also
unclear.15
The role of carbapenem-based treatment for CPE infection is
less clear since the introduction of novel b-lactamase inhibitors
with CPE activity. Whilst no direct head-to-head studies exist, the
combination of a b-lactam with a new b-lactamase inhibitor,
where susceptibilities are known, are expected to be more effica-
cious (e.g. meropenem/vaborbactam for KPC CPE and ceftazidime/
avibactam for OXA-48 CPE infections) and should be used in
preference to carbapenems.
Recommendations
• Carbapenems should not be used in preference to novel b-lac-
tam/b-lactamase inhibitors for treatment of invasive CPE
infections.
• Carbapenems may be used in combination with other agents,
including a second carbapenem. Outcomes are likely to be
improved if the organism appears susceptible on in vitro testing
(meropenem MIC 8 mg/L) or is close to the breakpoint.
High-dose meropenem and/or extended administration
therapy should be considered for organisms with an MIC of
4–8 mg/L.14,16
• There are insufficient data available to recommend the routine
use of dual carbapenem therapy to overcome CPE resistance
mechanisms.
3.6. Role of colistin in CPE infections
In a review of 105 cases of KPC infection, polymyxin monotherapy
was associated with higher rates of treatment failure compared
with polymyxin-based combination therapy [24/49 (49%) versus
14/56 (25%); P"0.01).3 That review did not give details of the
doses of polymyxin used. More recent analysis of colistin mono-
therapy (versus colistin plus meropenem) failed to demonstrate a
survival benefit with combination therapy. This was predominantly
infections with A. baumannii as the pathogen and in the subgroup
of Enterobacterales pathogens there was a non-significant
trend to favour combination therapy. However this subgroup was
underpowered to demonstrate non-inferiority in Enterobacterales
therefore the previous recommendations remain.5
Recommendations
• Where colistin is prescribed for the treatment of an invasive
CPE infection, it should be used in combination with one or
more other agents.
• Colistin therapeutic drug monitoring is recommended for all
patients treated with parenteral treatment to minimize risk of
toxicity.
3.7. Role of fosfomycin in CPE infections
Within the UK, the manufacturers advise that fosfomycin should
be used only when conventional therapy is considered inappropri-
ate and in combination for severe invasive infections. It has been
demonstrated that resistance to IV fosfomycin can develop rapidly
when it is used for monotherapy.17 An in vitro study investigating
the synergistic effect and impact on development of resistance of
fosfomycin with colistin, meropenem or gentamicin found that all
combinations showed improved bactericidal activity compared
with fosfomycin alone and prevented the development of resist-
ance in the majority of fosfomycin-susceptible isolates.18 In a
small case series of critical care patients with carbapenem-
resistant K. pneumoniae, IV fosfomycin (4 g every 6 h, adjusted for
renal impairment) was administered as combination therapy with
colistin (n"6), gentamicin (n"3) and piperacillin/tazobactam
(n"1).8 All-cause mortality was 18.1% but no patient developed a
relapse of infection.
Recommendations
• Fosfomycin is recommended to be used in combination with
other active agents when used for systemic therapy, due to its
vulnerability to acquired resistance.
3.8. Role of temocillin in CPE infections
Temocillin is not active against most CPE but remains effective
against KPC-producing Enterobacterales in in vitro studies.
Retrospective analysis of KPC bacteraemia cases (with MIC8 mg/L)
treated with temocillin showed acceptable clinical outcomes.19
Temocillin was predominantly used in combination therapy (with
amikacin, tigecycline or fosfomycin). Monotherapy with temocillin
has been trialled for urinary-sourced BSI with KPC identified
(S. Hughes, Chelsea & Westminster NHS Trust, unpublished data).
New EUCAST breakpoints were published in 2020; the lower
breakpoint for susceptibility has been reduced to 0.001 mg/L to
accommodate WT species. All WT species will be covered in the
intermediate or ‘susceptible, increased exposure’ group (MIC
,16 mg/L) with high-exposure temocillin (6 g/day).20 High urinary
concentrations may permit the continued use of temocillin 2 g
q12h for UTIs but higher doses (2 g q8h) are likely to be required for
non-urinary infections.
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Recommendations
• Temocillin may be considered in combination with other active
agents for KPC organisms where susceptibilities are known.
• The highest licensed dose of temocillin (6 g/day) is recom-
mended when treating invasive CPE infections of non-urinary
source.
• The use of monotherapy temocillin (4 g/day) for the treatment
of uncomplicated UTI with KPC-producing organisms should be
considered where susceptibilities are known.
3.9. Role of tigecycline in CPE infections
Tigecycline is licensed for use in complicated skin and soft tissue
infections (cSSTIs) and complicated intra-abdominal infections
(cIAIs). Tigecycline’s efficacy in respiratory, urinary and CNS infec-
tions is limited and the FDA highlights concerns about increased
mortality in off-licensed indications, particularly hospital-acquired
and ventilator-associated pneumonia.21 The reasons for these
findings are unknown, but poorer efficacy and safety than the
study comparators cannot be ruled out.
The EMA Committee for Medicinal Products for Human Use
(CHMP) has recommended that tigecycline should only be used
within its licensed indications as a pooled analysis of clinical
studies showed an increased mortality associated with tigecycline
versus comparator agents. A similar communication from the FDA
noted that the greatest increase in risk of mortality in the tigecyc-
line arm was seen in ventilator-associated pneumonia (19.1% ver-
sus 12.3%); this may be related to the lack of pseudomonal
coverage with tigecycline-based therapy.22
Combination therapy is advised for tigecycline-based therapies
for invasive CPE infection; the bacteriostatic nature of tigecycline
plus its high volume of distribution may result in suboptimal
bacteraemia clearance when used alone. High-dose therapy
(200 mg loading dose and 100 mg q12h) is often advised for re-
spiratory infection or for high-MIC pathogens. A meta-analysis
by Wang et al.23 (2017) identified monotherapy to be associ-
ated with increased mortality against combination therapy
[OR of 2.73 (95% CI 1.53–4.87) in six studies with a total of 250
patients]. This was replicated by the work of Ni et al.24 (2016),
which also identified superior ICU mortality outcomes for high-
dose tigecycline regimens when compared with standard dose
schedules [OR 12.48 (95% CI 2.06–75.43; P"0.006)]. In add-
ition, the authors found triple therapy with tigecycline-based
therapy may be superior to that of dual therapy, with lower
mortality rates identified on meta-analysis [OR 2.18 (95% CI
1.03–4.63; P"0.04)].
The new fully synthetic tetracycline, eravacycline, may
play a role in the treatment of MDR infections including
CPE. Eravacycline has similar activity to tigecycline against
Enterobacterales but with lower MICs (2-fold lower on average)
and has a reported lower gastrointestinal intolerance profile.
Eravacycline is unaffected by tet(M), tet(K) and tet(B), but MICs
are elevated in the presence of tet(A) and tet(X). In vitro data
show promise for CPE infections but a lack of clinical outcomes
data precludes current recommendation of eravacycline for
treatment of CPE invasive infections where other established
therapies are available.
Recommendations
• Where tigecycline is prescribed for the treatment of an invasive
CPE infection, it should be used in combination with one or
more other agents with anti-CPE activity.
• A high-dose tigecycline regimen (100 mg IV q12h) should be
considered when treating pathogens with high MIC (0.5–2 mg/L)
and/or in the treatment of respiratory infections.
3.10. Novel b-lactamase inhibitors in CPE infection
The majority of comparison studies of combination and monother-
apy for CPE infections occurred before the introduction of novel b-
lactam/b-lactamase inhibitor therapies to practice. These new
therapies provide a valuable addition to the armamentarium of
anti-CPE therapies.
3.10.1. Ceftazidime/avibactam
Ceftazidime/avibactam therapy for CPE infection has been well
described in clinical practice but data are limited to non-
randomized controlled trials and registry-based analysis. These
descriptive analyses show promise for ceftazidime/avibactam use
in invasive CPE infections, particularly those with OXA-48-
mediated resistant pathogens. The BSAC/HIS/BIA Working Party
on Gram-negative resistant pathogens advises some caution with
ceftazidime/avibactam use in KPC-producing resistant organisms
due to concerns about reduced clinical efficacy and selection of re-
sistant organisms (KPC-3).2
In vitro activity of ceftazidime/avibactam is well reported but
clinical data on the efficacy in severe infections caused by CPE are
still lacking. As of April 2020, only one prospective, observational
study had been published. Through the CRACKLE observational
study, a total of 38 and 99 patients treated for CPE infection with
ceftazidime/avibactam and colistin were analysed.25 Many
patients had confirmed bacteraemia (46%) or respiratory infec-
tions (22%) and combination therapy was more commonly seen
with colistin-based therapy (63% versus 94%). Ninety-seven per-
cent of isolates were KPC-producing K. pneumoniae. In-hospital
mortality at 30 days was 8% (3/38) and 33% (33/99) in the ceftazi-
dime/avibactam and colistin groups, respectively.25
In retrospective case studies, ceftazidime/avibactam has been
reported with mixed results. Results from haematology patients
with invasive KPC infection showed similar outcomes with mono-
therapy and combination therapy [33% (9/27) and 30% (10/33),
respectively] and similar outcomes to case series of salvage ther-
apy ceftazidime/avibactam in patients treated with a compassion-
ate use programme.26,27 The retrospective case series by Shields
et al.28 demonstrated clinical success, defined as no microbiologic-
al growth of CPE following 7 days of ceftazidime/avibactam, for
59% (22/37) and 30 day survival for 76% (28/37). No difference
was noted in clinical outcomes of monotherapy and combination
therapy with ceftazidime/avibactam [58% (15/26) and 64%
(7/11), respectively]. Development of ceftazidime/avibactam-
resistant isolates was identified in 30% (3/10) of patients without
microbiological cure, highlighting concerns about the develop-
ment of resistance, particularly for KPC-3 isolates. No prospective
randomized controlled studies are available to date to demon-
strate the efficacy of ceftazidime/avibactam against best available
therapy (BAT).
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The benefit of avibactam in combination with ceftazidime for
OXA-48-producing CPE with no co-located ESBL or AmpC resist-
ance is unclear. Ceftazidime monotherapy may be considered if
other resistant mechanisms are not found, as outlined by the
BSAC/HIS/BIA Working Party guidance on treatment of infections
caused by MDR Gram-negative bacteria.2
3.10.2. Meropenem/vaborbactam
A randomized, prospective, open-label, comparative study
(TANGO-II) compared meropenem/vaborbactam (2 g/2 g IV over
3 h, q8h) with best available antibiotic treatment (polymyxin, car-
bapenem, aminoglycoside or tigecycline alone or in combination;
or ceftazidime/avibactam alone) in adults with complex UTI
(cUTI), cIAI, hospital-acquired pneumonia, ventilator-associated
pneumonia or bacteraemia suspected or documented to be
caused by carbapenemase-resistant Enterobacterales (CRE).29
Due to small patient numbers (meropenem/vaborbactam arm,
n"32; best available antibiotic arm, n"15) this trial was a de-
scriptive study following on from TANGO-I and although no formal
power or sample size calculations were performed, a modified ITT
(mITT) analysis was undertaken.30 No significant difference
between meropenem/vaborbactam and best available antibiotic
treatment was found in cure rate at the end of treatment (mITT
66% versus 33%; P"0.04) and all-cause mortality at 28 days
(mITT 15.6% versus 33.3%, 95% CI of difference#44.7% to 9.3%;
P"0.20). Higher rates of nephrotoxicity were noted in the com-
parator treatment arm where the use of well-known nephrotoxic
agents such as colistin, polymyxin and/or aminoglycosides was
prevalent (10 of 14 patients).
More recently, in a real-world, retrospective, non-comparative,
multicentre observational study of meropenem/vaborbactam in
40 patients with CRE infections in the USA,7 clinical success was
achieved in 70% of patients. Failures were associated with high
APACHE-II score, inactive empirical therapy (before meropenem/
vaborbactam started) and single-agent empirical therapy. It is
possible that respiratory infections and SSTIs were also more prone
to treatment failure and recurrence.
Whilst promising trends to improvement with meropenem/
vaborbactam are reported, the design of these studies means that
firm conclusions cannot be made and the evidence supporting the
use of meropenem/vaborbactam is still limited.7,29–31
3.10.3. Imipenem/cilastatin/relebactam (IMI/REL)
This triple combination therapy combines the well-established
imipenem/cilastatin combination with the novel b-lactamase in-
hibitor, relebactam. Relebactam provides stability against some
class A carbapenemases (e.g. KPC-2) thus protecting imipenem’s
activity.32,33 Cilastatin is an enzyme with no antibacterial proper-
ties, which blocks renal metabolism of imipenem and thus
maintains adequate urinary imipenem levels for therapeutic
effect. This combination product was approved by the FDA and
EMA in 2019 for treatment of cUTI and cIAI where limited alterna-
tive treatment alternatives exist. Whilst relebactam shares a
similar structure to avibactam, the IMI/REL combination provides
no additional OXA-48, MBL or GES activity to carbapenems alone.
Relebactam provides potent inhibition of KPC enzymes in vitro.
At present, it is unclear whether relebactam provides additional
activity for KPC-3 enzymes resistant to avibactam.
The Phase III study compared the use of IMI/REL (n"31)
versus imipenem/cilastatin plus colistin (n"16) for carbapenem-
resistant pathogens (all isolates were IMI/REL- or colistin-
susceptible in vitro).32 Patients were treated for hospital-acquired
pneumonia/ventilator-associated pneumonia, cUTI or cIAI for
5–21 days and the primary outcome, study-defined clinical cure,
was similar in both groups (71% and 70% in IMI/REL and colistin
groups, respectively). Mortality (28 day) and treatment-related ad-
verse events were numerically lower in the IMI/REL group (10%
versus 30% and 16% versus 31%, respectively). Treatment-
emergent nephrotoxicity was lower with IMI/REL compared with
the colistin group (10% versus 56%, respectively; P"0.002).
However, most infections were non-CPE related (77% infections
due to Pseudomonas) and drawing conclusions on IMI/REL activity
for treatment of Enterobacterales is challenging.
3.10.4. Aztreonam in combination with avibactam
A combination product is not currently on the market and is await-
ing Phase III clinical trial completion. In the absence of a dedicated
combination product, the off-label use of aztreonam prescribed in
combination with ceftazidime/avibactam has been used to treat
MBL infections. The rationale for this regimen is to combine ceftazi-
dime/avibactam to stabilize aztreonam’s activity against class B
MBLs and particularly against any co-located ESBL/AmpC resist-
ance mechanisms that may inhibit aztreonam alone. Whilst prom-
ising in vitro data exist for this combination, robust evidence-based
practice is severely limited.34 In patients with MBL infections with
limited treatment options available, this combination therapy may
be considered.
3.10.5. Ceftolozane/tazobactam
The ceftolozane/tazobactam combination provides no additional
activity for CPE organisms. It may have a role in non-
carbapenemase-producing organisms where other carbapenem
resistance mechanisms are present (e.g. porin loss in
Pseudomonas spp.).2 This is outside the scope of this review and is
not discussed in the monographs.
Recommendations
• Novel b-lactam/b-lactamase inhibitor combination therapies
may be considered for monotherapy or in combination therapy
for treatment of invasive CPE infections.
• Meropenem/vaborbactam is recommended for treatment of in-
vasive infections caused by KPC-producing resistant
Enterobacterales.
• Ceftazidime/avibactam is recommended for treatment of inva-
sive infections caused by KPC- and OXA-48-producing resistant
Enterobacterales. Isolates with a KPC-3 resistance profile
should be treated with caution with ceftazidime/avibactam, as
outlined by the BSAC Expert Committee.
• Aztreonam in combination with avibactam may be considered
as a salvage treatment option for MBL-producing
Enterobacterales where other licensed therapies are unavailable.
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3.11. Novel siderophore cephalosporin therapy in CPE
infection
The unpublished CREDIBLE-CR study compares use of cefiderocol
largely as monotherapy (80%) in a randomized, open-label trial
(n"118) versus standard-of-care treatment for carbapenem-
resistant Gram-negative bacterial BSI, hospital-acquired pneumo-
nia and cUTI infections (data presented to FDA but not published in
a peer-reviewed journal at time of review; M. Bassetti, M. Ariyasu,
B. Binkowitz, T. D. Nagata, R. M. Echols, Y. Matsunaga, K. Toyoizumi,
Y. Doi, unpublished data). A higher all-cause mortality rate was
observed with cefiderocol treatment (versus BAT). The 28 day all-
cause mortality was higher in patients treated with cefiderocol
than in patients treated with BAT [25/101 (24.8%) versus 9/49
(18.4%), treatment difference 6.4%, 95% CI #8.6 to 19.2]. All-
cause mortality remained higher in patients treated with cefidero-
col than in patients treated with BAT through to Day 49 [34/101
(33.7%) versus 10/49 (20.4%), treatment difference 13.3%, 95%
CI #2.5 to 26.9]. A high prevalence of A. baumannii infections
(55%) was identified through this study and the applicability of
these results to CPE remains uncertain. The EMA and FDA advise
that cefiderocol should only be used when alternative therapies
are not available.35,36
In a series of multinational surveillance studies, cefiderocol inhib-
ited 97% of all carbapenem-non-susceptible Enterobacteriaceae,
including 91.1% of ceftazidime/avibactam-resistant strains, at a
concentration of 4 mg/L.37 This novel therapy undoubtably has
a role to play in the management of complex CPE infections,
particularly those with difficult-to-treat MBLs. However, identifying
optimum combination therapy remains a challenge.
Recommendations
• Novel siderophore cephalosporin-based therapy may be con-
sidered for combination therapy for invasive CPE infections
including Ambler class B-expressing pathogens (NDM, IMP and
VIM resistance mechanisms).
3.12. Aminoglycosides
3.12.1. Amikacin and gentamicin
Resistance to aminoglycosides varies depending on the resistance
mechanism present. Gentamicin resistance mechanisms are fre-
quently encountered with metallo-enzyme producers (.60%) and
non-metallo-enzyme producers (40%). Increased activity is seen
with amikacin for CPE organisms, as reported in the ESPAUR 2017
report.38 16S rRNA methyltransferase enzymes (16S RMTases) are
often co-located with CPE, notably NDM carbapenemase, and con-
fer high-level resistance to all currently licensed aminoglycosides.
Where phenotypic susceptibilities exist, aminoglycosides
can be used to treat CPE infections. The majority of case reports
advise an aminoglycoside (often amikacin) in combination with
another active antimicrobial for invasive CPE infection. The site of
infection is likely to be the main determinant of suitability of an
aminoglycoside-based treatment; tissue penetration in the lung,
brain and bone and joint may be suboptimal for maximum bacteri-
cidal effects of aminoglycoside therapy.
3.12.2. Plazomicin
Plazomicin is a semi-synthetic aminoglycoside derived from siso-
micin. Plazomicin evades almost all aminoglycoside-modifying
enzymes but is inactive if 16S RMTases are present.
The CARE study (published only in correspondence at the time
of review) directly compares plazomicin IV to colistin IV (both in
combination with either tigecycline or meropenem) in patients
with BSI or hospital-acquired or ventilator-associated bacterial
pneumonia caused by suspected or confirmed CRE.39 This multi-
centre, randomized, open-label trial reports a numerical lower
mortality at follow-up and superior clinical cure with plazomicin-
based therapy (n"18 for plazomicin). Further studies are required
to confirm the benefits of plazomicin for invasive infections.
Recommendations
• Where phenotypic susceptibilities are available, aminoglyco-
sides (including plazomicin) can be used as part of combination
therapy to treat CPE infections.
• Aminoglycoside antibiotics should be considered for treatment
of UTIs where susceptibilities allow.
4. Drug dosing information
Optimizing dosing strategies to give the highest drug exposure
according to pharmacokinetic and pharmacodynamic parameters
is recommended. EUCAST breakpoint data and dosing strategies
are adopted throughout these recommendations where available.
The antimicrobial monographs (see Appendix S1) provide infor-
mation on how optimal dosing can be achieved. Please note that
some recommendations reflect dosing strategies not covered by
the product licence. For details of side effects and interactions
please refer to the relevant Summary of Product Characteristics
and the current BNF.
5. Limitations
Due to the lack of randomized controlled trials the recommenda-
tions in this guide are based on limited or low-quality evidence.
However, it is intended as a pragmatic practical guide based on the
best information available.
Meta-analyses show there is lack of consistency in outcome
data. When well-conducted meta-analyses/review papers collat-
ing data on outcomes from individual studies were available these
were used in preference.
Due to the heterogeneity and low patient numbers in the stud-
ies it is not possible to compare the outcomes of different combin-
ation therapies.
The majority of the studies report on KPC-producing K. pneumo-
niae as this is the most common CPE mechanism found within the
USA where the majority of the literature is reported.
6. Conclusions
The management of infections associated with CPE remains a
challenge for responsible clinicians and infection teams. Early iden-
tification and susceptibility testing are essential for the prompt ini-
tiation of effective antimicrobial treatment. As outlined by the
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BSAC/HIS/BIA Working Party on Gram-negative resistant patho-
gens, the selection of antimicrobial treatment based on suscepti-
bility testing is the optimum strategy for treating infections caused
by CPE infection. Due to the array of resistance mechanisms and
the prevalence of multiple classes within the UK, no universal
treatment option is available and bespoke antimicrobial therapy is
required for each infected patient. This guidance provides a
summary of the most commonly used therapies for CPE infections
and provides expert advice on options for optimizing therapy to
maximize efficacy whilst minimizing toxicity.
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